(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

Inclusion Criteria:

• Male and female patients 18 to 74 years of age, who are able to understand andvoluntarily provide written informed consent

• Completed all Final Visit assessments for study CB-01-02/01 (NCT00679432) and are notin clinical remission

• Diagnosis of ulcerative colitis of mild to moderate severity with an UlcerativeColitis Disease Activity Index (UCDAI) <or= 10 according to Sutherland

• Females of child-bearing potential must have had a serum pregnancy test performed atthe Final Visit of the parent study, and must use an acceptable contraceptive methodthroughout the treatment period. Female subjects must also not be activelybreast-feeding through the entire study period.

• Ability to comprehend the full nature and purpose of the study, including possiblerisks and side effects

• Ability to co-operate with the investigator and to comply with the requirements of theentire study

Exclusion Criteria:

• Did not complete study CB-01-02/01

• Achieved clinical remission in study CB-01-02/01

• Patients with severe ulcerative colitis (UCDAI >10)

• Patients with infectious colitis

• Evidence or history of toxic megacolon

• Severe anemia, leucopenia, or granulocytopenia

• Use of immunosuppressive agents in the last 8 weeks before the study

• use of anti-tumor necrosis factor alpha agents in the last three months

• Concomitant use of any rectal preparation for the treatment of ulcerative colitis

• Concomitant use of antibiotics

• Concurrent use of cytochrome P-450 3A4 (CYP3A4) inducers and CYP3A4 inhibitors.

• Patients with verified, presumed of expected pregnancy or ongoing lactation

• Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiencyand/or severe impairment of the bio-humoral parameters (i.e., 2x upper limit of normalfor alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltranspeptidase, or creatinine)

• Patients with severe disease(s) in other organs of systems

• Patients with local of systemic complications of other pathological states requiring atherapy with corticosteroids and/or immunosuppressive agents

• Patients diagnosed with Type 1 diabetes

• Patients diagnosed with or with a family history of glaucoma

• Patients with known hepatitis B, hepatitis C, or with human immunodeficiency virus (HIV), according to the local privacy policy

• Any other medical condition that in the principal investigator's opinion would makethe administration of the study drug or study procedures hazardous to the subject orobscure the interpretation of adverse events